RGA study highlights potential of incretin-based therapies to improve global health outcomes
Reinsurance News - Nov 13, 2025
Reinsurance Group of America, Incorporated, a provider of life and health reinsurance solutions, has released new research that evaluates the potential effects of incretin-based therapies, including GLP-1 medications, on mortality and morbidity. These drugs, used for both weight management and diabe...
Recommended Articles
Posted: Nov 13, 2025
Descartes Underwriting, a specialist in corporate parametric re/insurance solutions for climate and...
Posted: Nov 13, 2025
UK-based flood science specialist JBA Risk Management has launched a high-resolution US inland flood...
Posted: Nov 13, 2025
AM Best has upgraded the Financial Strength Ratings of Greenlight Reinsurance, Ltd. (Cayman Islands)...